GH Research PLC Responds to FDA Clinical Hold for GH001
Ticker: GHRS · Form: 6-K · Filed: Jun 20, 2025 · CIK: 1855129
Sentiment: neutral
Topics: regulatory, clinical-trial, fda
TL;DR
GH Research PLC submitted its response to the FDA's clinical hold on GH001, aiming to get the IND back on track.
AI Summary
On June 20, 2025, GH Research PLC announced it submitted a complete response to the FDA regarding the clinical hold on its Investigational New Drug Application (IND) for GH001. This submission aims to resolve the issues that led to the hold, allowing the company to potentially proceed with clinical trials for GH001.
Why It Matters
This filing is significant as it indicates GH Research PLC is actively working to lift the clinical hold on its GH001 drug candidate, potentially paving the way for future clinical development and market entry.
Risk Assessment
Risk Level: medium — The clinical hold indicates potential issues with the drug candidate or trial design, and the success of the response is not guaranteed.
Key Players & Entities
- GH Research PLC (company) — Registrant
- GH001 (drug_candidate) — Investigational New Drug Application
- U.S. Food and Drug Administration (company) — Regulatory Agency
- FDA (company) — Regulatory Agency Abbreviation
- June 20, 2025 (date) — Submission Date
FAQ
What specific issues did the FDA raise that led to the clinical hold on GH001?
The filing states that GH Research PLC submitted a complete response to the previously announced clinical hold, but does not specify the exact issues raised by the FDA.
When was the original clinical hold announced by GH Research PLC?
The filing mentions a 'previously announced clinical hold' but does not provide the specific date of that announcement.
What is the expected timeline for the FDA's review of GH Research PLC's response?
The filing does not provide any information regarding the expected timeline for the FDA's review of the submitted response.
What is GH001?
GH001 is an Investigational New Drug (IND) for which GH Research PLC is seeking approval to proceed with clinical trials.
What is the significance of submitting a 'complete response' to the FDA?
Submitting a complete response indicates that GH Research PLC believes it has addressed all the deficiencies or concerns raised by the FDA regarding the IND for GH001.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 20, 2025 regarding GH Research PLC (GHRS).